CLINICAL TRIALS PROFILE FOR ASTEPRO ALLERGY
✉ Email this page to a colleague
All Clinical Trials for ASTEPRO ALLERGY
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00720382 ↗ | A Study to Evaluate the Safety and Tolerability of a Nasal Spray to Treat Perennial Allergic Rhinitis | Completed | Meda Pharmaceuticals | Phase 3 | 2007-03-01 | The purpose of this study is to determine if one allergy treatment (0.15% azelastine hydrochloride) is as safe as mometasone furoate (nasonex) alone. |
| NCT00783432 ↗ | Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis | Completed | Meda Pharmaceuticals | Phase 3 | 2006-07-01 | The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride) |
| NCT01368445 ↗ | A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies | Completed | Meda Pharmaceuticals | Phase 3 | 2006-08-01 | The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice daily in patients with seasonal allergic rhinitis. |
| NCT01880840 ↗ | Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR | Completed | Novella Clinical | Phase 4 | 2013-06-01 | The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know which group each is in. |
| NCT01880840 ↗ | Safety of Astepro 0.15% Nasal Spray and Astepro 0.1% Nasal Spray in Children Ages >6 Months to <6 Years With AR | Completed | Meda Pharmaceuticals | Phase 4 | 2013-06-01 | The purpose of this study is to compare the safety of 2 different doses of the investigational use of an allergy medication (Astepro Nasal Spray) in the treatment of allergic rhinitis (AR). This is an open-label study; that is, parent and child will know which group each is in. |
| NCT06008860 ↗ | A Pilot Clinical Evaluation of Astepro® Nasal Spray for Management of Early SARS-CoV-2 Infection | Recruiting | University of Chicago | Phase 4 | 2023-07-01 | The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for ASTEPRO ALLERGY
Condition Name
Clinical Trial Locations for ASTEPRO ALLERGY
Trials by Country
Clinical Trial Progress for ASTEPRO ALLERGY
Clinical Trial Phase
Clinical Trial Sponsors for ASTEPRO ALLERGY
Sponsor Name
